Infobelt Omni Archive Manager’s Support for 21 CFR Part 11 Compliance in Pharmaceutical Environments
Executive Summary
In the highly regulated pharmaceutical sector, where data integrity directly impacts patient safety and FDA approvals, electronic archiving solutions must adhere to 21 CFR Part 11 to treat digital records as equivalents to paper. Infobelt’s Omni Archive Manager (OAM™) emerges as a versatile platform, leveraging AI, RPA, and NLP to manage the full data lifecycle—from acquisition to defensible destruction—across structured, semi-structured, and unstructured formats.
OAM’s robust security, governance, and retention features align closely with the regulation’s controls, as evidenced by compliance with analogous standards like HIPAA and SEC Rule 17a-4. This report analyzes OAM’s capabilities against Part 11 subsections, using a detailed mapping to demonstrate practical support. For pharma firms, OAM’s scalability (MB to petabytes) and deployment flexibility position it as a cost-effective enabler, though user-led validation remains essential given FDA’s enforcement discretion.
Regulatory Context and Applicability
Enacted in 1997 and refined by 2003/2018 FDA guidances, 21 CFR Part 11 governs electronic records under predicate rules like CGMP (21 CFR Parts 210/211), ensuring trustworthiness via validation, security, and auditability. It applies to archiving software for pharma data (e.g., clinical trials, batch logs) that is created, modified, maintained, or retrieved electronically. OAM fits this scope as a PaaS for compliant archiving, emphasizing “defensible” practices that mitigate risks like data breaches or loss—critical amid rising cyber threats, with pharma facing 25% of industry attacks per 2025 reports. Unlike niche tools, OAM’s unified approach avoids integration silos, supporting global harmonization with EU Annex 11.
OAM’s design caters to regulated users: pre-built connectors ingest from databases, ERPs, and SaaS; OmniBot™ automates management; and AQL Copilot™ enables intuitive queries. Testimonials from Fortune 500 banks highlight its handling of 23 trillion records across 300+ apps, implying pharma-scale reliability. Storage compression yields 95% savings, freeing resources for compliance efforts.
Detailed Compliance Alignment
OAM’s features exceed basic retention for regs like FINRA and MiFID, extending to Part 11 via immutable storage and AI-driven governance. Below is an expanded mapping, incorporating FDA criteria with OAM specifics. This risk-based view prioritizes high-impact controls (e.g., audit trails, cited in 30% of warnings).
This table covers §11.10 controls comprehensively; OAM’s AI/ML (e.g., sentiment analysis for classification) adds proactive compliance, analyzing trends to preempt risks.